Table 1.
Analyses of genetic mutations or amplification in antemortem and postmortem specimens
| Histological type | Antemortem specimen
|
Postmortem specimen
|
|---|---|---|
| Adenocarcinoma | Giant cell carcinoma | |
| EGFR exon18 G719X | (−) | (−) |
| EGFR exon19 Deletion | (+) | (+) |
| EGFR exon20 T790M | (−) | (−) |
| EGFR exon21 L858R | (−) | (−) |
| EGFR exon21 L861Q | (−) | (−) |
| MET amplification | (+) (5.2/cell) | (+) (15.4/cell) |
| PIK3CA exon9 E542K | (−) | (−) |
| PIK3CA exon9 E545K/D | (−) | (−) |
| PIK3CA exon20 H1047R | (−) | (−) |
Notes: +, positive for genetic mutation or amplification; −, negative for genetic mutation or amplification. EGFR exon 19 deletion was observed in both specimens. MET amplification was also observed in both specimens, but MET gene copy numbers of postmortem tumor cells were higher than those of antemortem tumor cells. The other genetic mutations were negative in both specimens.
Abbreviations: EGFR, epidermal growth factor receptor; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha.